Peptide Pillar · Recovery & Repair
What the research actually shows about BPC-157
BPC-157 is one of the most-discussed peptides on the internet and one of the least-studied in humans. Here is the honest read: the animal and mechanistic case is genuinely interesting; the human case is, so far, thin.
Evidence at a glance
Strength of evidence
Human vs animal data
Regulatory status
Research-only · not FDA-approvedWhat we know
Multiple animal studies have demonstrated BPC-157's protective effects on the gastrointestinal mucosa, with mechanisms appearing to involve VEGF-mediated angiogenesis and nitric-oxide signaling. The animal literature is substantial — a 2025 systematic review found 36 studies, only 1 of them in humans.
Preliminary human evidence remains limited to small, mostly unblinded reports. There is no published phase-3 human trial for any of the recovery or gut-repair uses the compound is marketed for online.
What a clinician sees that the literature doesn't say
Reviewer note: published studies use a narrower range of contexts than practitioners do; where clinical observation informs a section, we say so explicitly and label it as observation, not evidence.
Questions to ask your clinician about BPC-157
- Given that nearly all the evidence is from animal models, what would change your recommendation?
- What baseline labs and monitoring would you want before and during a trial?
- What are the known interactions with my current medications?
- What is the exit plan if I see no benefit in a defined window?
Citations
- Sikiric et al. 2018
- Chang et al. 2020
- 2025 systematic review (36 studies, 1 human)
We don’t prescribe. We synthesize the research so you can have an informed conversation with your prescriber. And if the honest read of the evidence is “not yet” or “probably not worth it for you” — we’ll tell you that too.